Literature DB >> 19528959

Clostridium difficile infection: new developments in epidemiology and pathogenesis.

Maja Rupnik1, Mark H Wilcox, Dale N Gerding.   

Abstract

Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19528959     DOI: 10.1038/nrmicro2164

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  119 in total

1.  Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection.

Authors:  Mary Y Hu; Kianoosh Katchar; Lorraine Kyne; Seema Maroo; Sanjeev Tummala; Valley Dreisbach; Hua Xu; Daniel A Leffler; Ciarán P Kelly
Journal:  Gastroenterology       Date:  2008-12-13       Impact factor: 22.682

Review 2.  Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review.

Authors:  Tim Planche; Adamma Aghaizu; Richard Holliman; Peter Riley; Jan Poloniecki; Aodhán Breathnach; Sanjeev Krishna
Journal:  Lancet Infect Dis       Date:  2008-11-01       Impact factor: 25.071

3.  Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Authors:  Jacques Pépin; Nathalie Saheb; Marie-Andrée Coulombe; Marie-Eve Alary; Marie-Pier Corriveau; Simon Authier; Michel Leblanc; Geneviève Rivard; Mathieu Bettez; Valérie Primeau; Martin Nguyen; Claude-Emilie Jacob; Luc Lanthier
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

4.  Surface layer proteins from Clostridium difficile induce inflammatory and regulatory cytokines in human monocytes and dendritic cells.

Authors:  Clara Maria Ausiello; Marina Cerquetti; Giorgio Fedele; Fabiana Spensieri; Raffaella Palazzo; Maria Nasso; Simona Frezza; Paola Mastrantonio
Journal:  Microbes Infect       Date:  2006-08-08       Impact factor: 2.700

5.  Susceptibility of hamsters to human pathogenic Clostridium difficile strain B1 following clindamycin, ampicillin or ceftriaxone administration.

Authors:  Michelle Merrigan; Susan Sambol; Stuart Johnson; Dale N Gerding
Journal:  Anaerobe       Date:  2003-04       Impact factor: 3.331

6.  Epidemiology of community-acquired Clostridium difficile-associated diarrhea.

Authors:  L R Hirschhorn; Y Trnka; A Onderdonk; M L Lee; R Platt
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

7.  Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008.

Authors:  E J Kuijper; F Barbut; J S Brazier; N Kleinkauf; T Eckmanns; M L Lambert; D Drudy; F Fitzpatrick; C Wiuff; D J Brown; J E Coia; H Pituch; P Reichert; J Even; J Mossong; A F Widmer; K E Olsen; F Allerberger; D W Notermans; M Delmée; B Coignard; M Wilcox; B Patel; R Frei; E Nagy; E Bouza; M Marin; T Akerlund; A Virolainen-Julkunen; O Lyytikäinen; S Kotila; A Ingebretsen; B Smyth; P Rooney; I R Poxton; D L Monnet
Journal:  Euro Surveill       Date:  2008-07-31

8.  gp96 is a human colonocyte plasma membrane binding protein for Clostridium difficile toxin A.

Authors:  Xi Na; Ho Kim; Mary P Moyer; Charalabos Pothoulakis; J Thomas LaMont
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

9.  A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates.

Authors:  M Rupnik; V Avesani; M Janc; C von Eichel-Streiber; M Delmée
Journal:  J Clin Microbiol       Date:  1998-08       Impact factor: 5.948

10.  Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea.

Authors:  Mark H Wilcox; Jane Freeman; Warren Fawley; Sarah MacKinlay; Alex Brown; Katrina Donaldson; Oliver Corrado
Journal:  J Antimicrob Chemother       Date:  2004-05-26       Impact factor: 5.790

View more
  563 in total

1.  Interleukin-22 regulates the complement system to promote resistance against pathobionts after pathogen-induced intestinal damage.

Authors:  Mizuho Hasegawa; Shoko Yada; Meng Zhen Liu; Nobuhiko Kamada; Raúl Muñoz-Planillo; Nhu Do; Gabriel Núñez; Naohiro Inohara
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota.

Authors:  Mary C Rea; Orla O'Sullivan; Fergus Shanahan; Paul W O'Toole; Catherine Stanton; R Paul Ross; Colin Hill
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models.

Authors:  Jennifer Steele; Kevin Chen; Xingmin Sun; Yongrong Zhang; Haiying Wang; Saul Tzipori; Hanping Feng
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 4.  Allosteric regulation of protease activity by small molecules.

Authors:  Aimee Shen
Journal:  Mol Biosyst       Date:  2010-06-10

Review 5.  Bacteriocin production: a probiotic trait?

Authors:  Alleson Dobson; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Appl Environ Microbiol       Date:  2011-10-28       Impact factor: 4.792

6.  Medical microbiology: A toxin contest.

Authors:  Jimmy D Ballard
Journal:  Nature       Date:  2010-10-07       Impact factor: 49.962

Review 7.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

8.  Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans.

Authors:  Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei
Journal:  Pharmacotherapy       Date:  2018-02-22       Impact factor: 4.705

Review 9.  Clostridium difficile spore biology: sporulation, germination, and spore structural proteins.

Authors:  Daniel Paredes-Sabja; Aimee Shen; Joseph A Sorg
Journal:  Trends Microbiol       Date:  2014-05-07       Impact factor: 17.079

10.  Identification and characterization of glycoproteins on the spore surface of Clostridium difficile.

Authors:  Philippa C R Strong; Kelly M Fulton; Annie Aubry; Simon Foote; Susan M Twine; Susan M Logan
Journal:  J Bacteriol       Date:  2014-05-09       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.